Fermenta Biotech Limited , a leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes, has achieved a significant milestone in its innovation journey. The company recently announced that the Indian Patent Office has granted a patent for its proprietary plant-based Vitamin D3 manufacturing process, developed by its in-house Research and Development team.

Breakthrough in Sustainable Nutrition

The newly patented process enables Fermenta Biotech to produce vegan and vegetarian-friendly Vitamin D3, addressing the growing demand for sustainable nutrition solutions in the nutraceutical and food fortification sectors. This development strengthens Fermenta Biotech's intellectual property portfolio and reinforces its position as a key player in the global Vitamin D3 market.

Market Impact and Global Reach

Fermenta Biotech Limited, which serves over 400 customers across 60 countries, is poised to capitalize on the increasing trend towards plant-based and ethically sourced nutritional ingredients. The company's innovative approach aligns with the accelerating global demand for sustainable nutrition options, particularly in markets where plant-derived ingredients command premium prices and growing market share.

Leadership Perspective

Prashant Nagre, Managing Director of Fermenta Biotech Limited, expressed pride in this achievement, stating, "The grant of this patent is a proud milestone in our journey of innovation. It reflects our dedication to addressing evolving consumer needs with environmentally conscious solutions."

Nagre further emphasized the significance of this development for both the company and the country, adding, "Plant-based Vitamin D3 represents the future of nutrition, and this patent reinforces our ability to deliver differentiated offerings that create long-lasting impact for both our partners and society at large. It also strengthens India's role as a hub for pioneering industrial innovation, showcasing how local science can contribute to global wellness."

Strategic Implications

This patent not only enhances Fermenta Biotech's competitive edge but also diversifies its pioneering legacy in biotechnology and nutrition. It supports the company's vision to address global nutrition gaps while maintaining scientific excellence and sustainability leadership.

The development of this plant-based Vitamin D3 manufacturing process demonstrates Fermenta Biotech's commitment to innovation and its ability to adapt to changing market demands. As the world increasingly shifts towards sustainable and plant-based alternatives, Fermenta Biotech is well-positioned to meet these evolving needs in the nutritional supplement and food fortification industries.

About Fermenta Biotech Limited

Founded in 1951, Fermenta Biotech Limited has established itself as a key player in the nutrition industry. The company's portfolio includes customized premixes, Fortified Rice Kernel (FRK), and other nutritional ingredients. Fermenta Biotech's manufacturing facilities, located in Kullu, Dahej, and Tirupati, are certified by global accreditations, and its world-class R&D centre is situated in Thane.

With this latest patent, Fermenta Biotech Limited continues to demonstrate its commitment to innovation and sustainability in the global nutrition market, further solidifying its position as a leader in the Vitamin D3 industry.

Fermenta Biotech Limited has announced the approval of its unaudited financial results for the first quarter. The company's Board of Directors convened on August 12 to review and approve the financial statements for both standalone and consolidated operations for the quarter ended June 30.

Financial Performance

Fermenta Biotech reported a significant improvement in its financial performance for Q1. The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) reached 282.00 million rupees, compared to 8.00 million rupees in the same period last year. This represents a substantial year-over-year growth. The EBITDA margin also saw a remarkable improvement, increasing to 20.70% from 1.03% in the previous year.

Board Meeting Details

The board meeting, which took place at the company's registered office, commenced at 11:30 a.m. and concluded at 12:45 p.m. Indian Standard Time (IST). This prompt turnaround demonstrates Fermenta Biotech's commitment to efficient corporate governance and timely disclosure of financial information.

Financial Results and Auditor's Review

The unaudited financial results, encompassing both standalone and consolidated figures, were scrutinized and approved during the meeting. In compliance with regulatory requirements, Fermenta Biotech has submitted Limited Review Reports on these results. The reports were issued by the company's statutory auditors, SRBC & Co. LLP, Chartered Accountants.

Regulatory Compliance

The announcement of these financial results is in accordance with Regulations 30 and 33 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. This adherence to regulatory standards underscores Fermenta Biotech's commitment to transparency and corporate responsibility.

Company Leadership

The official communication was signed by Varadvinayak Khambete, who serves as the Company Secretary & Head - Legal for Fermenta Biotech Limited. Mr. Khambete, holding the Membership No. A33861, plays a crucial role in ensuring the company's compliance with legal and regulatory requirements.

Fermenta Biotech Limited, with its corporate identity number L99999MH1951PLC008485, maintains its registered office at A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India. The company operates manufacturing facilities in Himachal Pradesh and Gujarat, showcasing its diverse operational footprint across India.